- Conditions
- Lung Cancer Stage IV
- Interventions
- Blood and tumor tissue analysis, Clinical response.
- Other
- Lead sponsor
- Holy Cross Hospital, Maryland
- Other
- Eligibility
- 18 Years to 70 Years
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 66
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Cervical Carcinoma, Metastatic Ovarian Carcinoma, Malignant Uterine Neoplasm, Vulvar Cancer, Invasive Breast Cancer, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Vulvar Carcinoma, Stage IV Cervical Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vulva Squamous Cell Carcinoma
- Interventions
- Blood draws, QLQ-CIPN20 Survey, PR-CTCAE Survey
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Prostate Carcinoma
- Interventions
- Biospecimen Collection, Laboratory Biomarker Analysis
- Procedure · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Interventions
- Specific T- Lymphocytes
- Biological
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 1 Month to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Melanoma
- Interventions
- cyclophosphamide, Mature dendritic cell vaccine
- Drug · Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Carcinoma, Renal Cell, Carcinoma, Urothelial
- Interventions
- Immune cell and CTC detection procedures
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Autologous alpha-DC1/TBVA vaccine, Cabozantinib
- Biological · Drug
- Lead sponsor
- Jodi Maranchie
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Acute Myeloid Leukemia
- Interventions
- CIML NK Cell Infusion, CD3+ T Cell Product Infusion, Leukapheresis
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Lymphoma
- Interventions
- rituximab, bortezomib, carboplatin, dexamethasone, etoposide, ifosfamide, polymerase chain reaction, western blotting
- Biological · Drug · Genetic
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 17
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 12 more
- Conditions
- Multiple Myeloma
- Interventions
- Spectra Optia Apheresis System
- Device
- Lead sponsor
- Terumo BCT
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Durham, North Carolina + 1 more
- Conditions
- Hypersensitivity Pneumonitis
- Interventions
- Bronchoscopy with lavage
- Other
- Lead sponsor
- Nabeel Hamzeh
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Interventions
- Manufactured Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Thomas Martin, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Cancer
- Interventions
- Aldesleukin, Sargramostim, therapeutic autologous lymphocytes
- Biological
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
- Interventions
- Bone marrow concentration device, Placebo procedure (sham)
- Device · Procedure
- Lead sponsor
- Zimmer Biomet
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Sacramento, California • Miami, Florida + 20 more
- Conditions
- Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
- Interventions
- CARv3-TEAM-E T cells
- Drug
- Lead sponsor
- Marcela V. Maus, M.D.,Ph.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- laboratory biomarker analysis, medical chart review
- Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hypoplastic Left Heart Syndrome
- Interventions
- Autologous (self) mononuclear cells derived from umbilical cord blood, Stage II Surgical repair
- Biological · Procedure
- Lead sponsor
- Timothy J Nelson, MD, PhD
- Other
- Eligibility
- Up to 12 Months
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 5 more
- Conditions
- Hematopoietic Stem Cell Transplantation
- Interventions
- Blood Draw
- Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Rheumatoid Arthritis
- Interventions
- Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
- Other · Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Asthma, HIV, Adiposity
- Interventions
- Blood draw, Questionnaires, Spirometry, Methacholine challenge test, Quantitative CT scans, Urine pregnancy test, Adipose biopsy, Exhaled nitric oxide measurement
- Procedure · Other · Radiation
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Myocardial Ischemia
- Interventions
- CLBS14 (low-dose), CLBS14 (high-dose), placebo injection
- Biological
- Lead sponsor
- Lisata Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
- Conditions
- Malignant Pleural Mesothelioma (MPM)
- Interventions
- cyclophosphamide, CAR T cells
- Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Prolymphocytic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies, AR-42
- Other · Drug
- Lead sponsor
- Amir Mortazavi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Glioblastoma
- Interventions
- Cognitive Assessment, Blood Collection, Bioenergetic Profiling
- Procedure · Diagnostic Test
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina